Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1ZYCA)

Drug Name

TALTOBULIN Drug Info

Synonyms

HTI-286; SPA-110 (trifluoroacetate salt); Taltobulin; N,3,3-Trimethyl-L-phenylalanyl-N1-[3-carboxy-1(S)-isopropyl-2(E)-butenyl]-N1,3-dimethyl-L-valinamide

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[1]

Cross-matching ID

PubChem CID: 6918637
CAS Number: CAS 228266-40-8
TTD Drug ID: DM1ZYCA

Molecule-Related Drug Atlas

Molecule Type:

DTT

DOT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Tubulin (TUB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[4]
Vinorelbine	DMVXFYE	Advanced cancer	2A00-2F9Z	Approved	[5]
Cabazitaxel	DMPAZHC	Breast cancer	2C60-2C65	Approved	[6]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[7]
Ixabepilone	DM2OZ3G	Breast cancer	2C60-2C65	Approved	[6]
Eribulin	DM1DX4Q	Breast cancer	2C60-2C65	Approved	[6]
Epothilon	DMITJRU	Ovarian cancer	2C73	Phase 3	[8]
DOLASTATIN-10	DMDUV1S	Solid tumour/cancer	2A00-2F9Z	Phase 2	[9]
BMS-188797	DML1CK2	Solid tumour/cancer	2A00-2F9Z	Phase 2	[10]
Indibulin	DM6OFJ8	Advanced sarcoma	2A60-2C35	Phase 2	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tubulin (TUB)	TTML2WA	NOUNIPROTAC	Inhibitor	[2]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Tubulin alpha-1B chain	OTA3CQ9X	TBA1B_HUMAN	Drug Response	[3]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019128)
2	Absolute configurations of tubulin inhibitors taltobulin (HTI-286) and HTI-042 characterized by X-ray diffraction analysis and NMR studies. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1535-8.
3	Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin. Mol Cancer Ther. 2004 Oct;3(10):1319-27.
4	Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(17):2513-31.
5	Vinca alkaloid and MDR1. Gan To Kagaku Ryoho. 2008 Jul;35(7):1086-9.
6	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
7	Vitamin K3 disrupts the microtubule networks by binding to tubulin: a novel mechanism of its antiproliferative activity. Biochemistry. 2009 Jul 28;48(29):6963-74.
8	Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
9	Synthesis and biological activity of chimeric structures derived from the cytotoxic natural compounds dolastatin 10 and dolastatin 15. J Med Chem. 1998 Apr 23;41(9):1524-30.
10	Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. Clin Cancer Res. 2003 Nov 1;9(14):5187-94.
11	2011 Pipeline of ZioPharm.